HC Wainwright Issues Pessimistic Forecast for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of ($2.83) for the quarter, down from their previous estimate of ($2.10). HC Wainwright currently has a "Buy" rating and a $405.00 price target on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals' Q2 2025 earnings at ($2.14) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($7.82) EPS, FY2026 earnings at $9.85 EPS, FY2027 earnings at $31.36 EPS, FY2028 earnings at $52.07 EPS and FY2029 earnings at $87.27 EPS.

Other equities research analysts also recently issued reports about the company. JMP Securities restated a "market outperform" rating and set a $427.00 price objective on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. B. Riley upgraded Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and lifted their price objective for the stock from $236.00 to $422.00 in a report on Thursday, February 27th. Cantor Fitzgerald restated a "neutral" rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 20th. Finally, Citigroup lifted their price objective on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $375.75.

Remove Ads

Madrigal Pharmaceuticals Stock Down 5.3 %

MDGL stock traded down $18.51 during midday trading on Monday, hitting $328.77. 344,823 shares of the company's stock were exchanged, compared to its average volume of 441,473. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals has a 12-month low of $189.00 and a 12-month high of $377.46. The firm has a 50 day moving average price of $324.17 and a 200-day moving average price of $287.02. The stock has a market capitalization of $7.26 billion, a price-to-earnings ratio of -13.11 and a beta of -0.38.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, beating the consensus estimate of ($4.32) by $1.61. The company had revenue of $103.32 million for the quarter, compared to analysts' expectations of $97.81 million.

Insider Transactions at Madrigal Pharmaceuticals

In related news, VP Robert E. Waltermire sold 442 shares of the business's stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $120,847.22. Following the completion of the transaction, the vice president now owns 5,058 shares in the company, valued at $1,382,907.78. The trade was a 8.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Rebecca Taub sold 1,689 shares of the business's stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $461,789.49. Following the transaction, the chief marketing officer now owns 457,310 shares of the company's stock, valued at $125,033,127.10. This represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,787 shares of company stock worth $7,351,029. 22.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDGL. Creative Planning boosted its position in Madrigal Pharmaceuticals by 2.7% during the 3rd quarter. Creative Planning now owns 3,299 shares of the biopharmaceutical company's stock valued at $700,000 after purchasing an additional 87 shares during the period. Nisa Investment Advisors LLC boosted its position in Madrigal Pharmaceuticals by 47.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 68 shares during the period. Verity Asset Management Inc. boosted its position in Madrigal Pharmaceuticals by 7.4% during the 3rd quarter. Verity Asset Management Inc. now owns 1,466 shares of the biopharmaceutical company's stock worth $311,000 after acquiring an additional 101 shares during the period. Assetmark Inc. boosted its position in Madrigal Pharmaceuticals by 8.3% during the 3rd quarter. Assetmark Inc. now owns 3,942 shares of the biopharmaceutical company's stock worth $837,000 after acquiring an additional 303 shares during the period. Finally, Victory Capital Management Inc. boosted its position in Madrigal Pharmaceuticals by 1.8% during the 3rd quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company's stock worth $486,000 after acquiring an additional 40 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.